###begin article-title 0
###xml 37 60 37 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pseudomonas aeruginosa </italic>
###xml 37 59 <span type="species:ncbi:287">Pseudomonas aeruginosa</span>
###xml 63 71 <span type="species:ncbi:9606">children</span>
CD14 C-159T and early infection with Pseudomonas aeruginosa in children with cystic fibrosis
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 21 44 21 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pseudomonas aeruginosa </italic>
###xml 426 439 426 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P.aeruginosa </italic>
###xml 607 620 605 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P.aeruginosa </italic>
###xml 709 721 707 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P.aeruginosa</italic>
###xml 21 43 <span type="species:ncbi:287">Pseudomonas aeruginosa</span>
###xml 85 93 <span type="species:ncbi:9606">patients</span>
###xml 245 253 <span type="species:ncbi:9606">children</span>
###xml 407 415 <span type="species:ncbi:9606">children</span>
###xml 426 438 <span type="species:ncbi:287">P.aeruginosa</span>
###xml 607 619 <span type="species:ncbi:287">P.aeruginosa</span>
###xml 709 721 <span type="species:ncbi:287">P.aeruginosa</span>
Early acquisition of Pseudomonas aeruginosa is associated with a poorer prognosis in patients with cystic fibrosis. We investigated whether polymorphisms in CD14, the lipopolysaccharide receptor, increase the risk of early infection. Forty-five children with cystic fibrosis were investigated with annual bronchoalveolar lavage (BAL) and plasma sCD14 levels. Plasma sCD14 levels were significantly lower in children from whom P.aeruginosa was subsequently isolated (492.75 mug/ml vs. 1339.43 mug/ml, p = 0.018). Those with the CD14 -159CC genotype had a significantly increased risk of early infection with P.aeruginosa suggesting that CD14 C-159T plays a role in determining the risk of early infection with P.aeruginosa.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 478 479 478 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 482 504 482 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pseudomonas aeruginosa</italic>
###xml 676 677 676 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 482 504 <span type="species:ncbi:287">Pseudomonas aeruginosa</span>
###xml 567 575 <span type="species:ncbi:9606">patients</span>
Cystic fibrosis (CF) is the most common serious, monogenic, autosomal recessive disease in Caucasians and results from mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR). CF is characterised by variable phenotypic expression, which is not entirely explained by the allelic heterogeneity of the pathogenic CFTR mutations, and there is accumulating evidence that much of this phenotypic diversity is due to the effect of modifier genes [1]. Pseudomonas aeruginosa, an environmental organism, is the most important pathogen in patients with CF as chronic infection results in a more rapid decline in lung function and reduced survival [2].
###end p 4
###begin p 5
###xml 130 143 130 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P.aeruginosa </italic>
###xml 457 458 457 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 678 679 678 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 896 897 896 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 130 142 <span type="species:ncbi:287">P.aeruginosa</span>
###xml 197 205 <span type="species:ncbi:9606">patients</span>
###xml 542 550 <span type="species:ncbi:9606">children</span>
CD14, a key gene of the innate immune system, functions as a receptor for lipopolysaccharide (LPS), a constitutive element of the P.aeruginosa cell wall, and is a potential modifier of severity in patients with CF. CD14 is expressed in both a membrane-bound form on macrophages, monocytes and neutrophils (mCD14) and soluble form in serum (sCD14). A polymorphism in the CD14 gene promoter (C-159T) has an allele frequency of approximately 50% in Europeans [3]. The -159C allele is associated with lower circulating levels of sCD14 in healthy children. Higher constitutive levels of mCD14 and sCD14 have been shown to increase the magnitude of airway neutrophil response to LPS [4], whereas CD14 receptor blockade results in a reduction in the deleterious systemic responses that occur in sepsis, due to a reduction in pro-inflammatory cytokines but at the expense of an increased bacterial load [5]. Hence, CD14 may play a pivotal role in determining the balance of infection and inflammation in CF. Increased expression of CD14 may be associated with more inflammation but a reduced bacterial load, whereas reduced expression may result in less inflammation but a greater bacterial load.
###end p 5
###begin p 6
###xml 21 34 21 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P.aeruginosa </italic>
###xml 21 33 <span type="species:ncbi:287">P.aeruginosa</span>
###xml 73 81 <span type="species:ncbi:9606">children</span>
We hypothesised that P.aeruginosa infection would be acquired earlier in children with the -159CC genotype.
###end p 6
###begin title 7
Methods
###end title 7
###begin p 8
###xml 457 470 457 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P.aeruginosa </italic>
###xml 43 51 <span type="species:ncbi:9606">children</span>
###xml 159 167 <span type="species:ncbi:9606">children</span>
###xml 360 368 <span type="species:ncbi:9606">children</span>
###xml 378 386 <span type="species:ncbi:9606">Children</span>
###xml 457 469 <span type="species:ncbi:287">P.aeruginosa</span>
A prospective, population-based, cohort of children with CF was recruited from the only tertiary paediatric hospital in Western Australia, which cares for all children with CF in the state. Annual bronchoscopy, performed through a laryngeal mask to minimise the risk of upper airway contamination, was done routinely from diagnosis until 7 years of age in all children with CF. Children diagnosed after the neonatal period, whose first BAL was positive for P.aeruginosa were excluded from this analysis, as in this situation it could not be determined when they had initially acquired this pathogen.
###end p 8
###begin p 9
###xml 45 57 45 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P.aeruginosa</italic>
###xml 273 274 273 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 372 384 372 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P.aeruginosa</italic>
###xml 4 12 <span type="species:ncbi:9606">children</span>
###xml 45 57 <span type="species:ncbi:287">P.aeruginosa</span>
###xml 340 348 <span type="species:ncbi:9606">children</span>
###xml 372 384 <span type="species:ncbi:287">P.aeruginosa</span>
###xml 438 446 <span type="species:ncbi:9606">children</span>
All children with a positive BAL culture for P.aeruginosa, which was defined as >10,000 CFU/ml, were admitted to hospital for further treatment. Blood was collected for genetic studies and subjects were genotyped for the CD14 promoter polymorphism as previously described [3]. Plasma samples taken at the time of the earliest BAL, when the children were not infected with P.aeruginosa, was available for measurement of sCD14 levels in 31 children. Plasma sCD14 levels were determined using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, USA).
###end p 9
###begin p 10
###xml 75 88 75 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P.aeruginosa </italic>
###xml 264 277 264 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P.aeruginosa </italic>
###xml 493 507 493 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. aeruginosa </italic>
###xml 75 87 <span type="species:ncbi:287">P.aeruginosa</span>
###xml 141 149 <span type="species:ncbi:9606">children</span>
###xml 219 227 <span type="species:ncbi:9606">children</span>
###xml 264 276 <span type="species:ncbi:287">P.aeruginosa</span>
###xml 493 506 <span type="species:ncbi:287">P. aeruginosa</span>
The Kaplan-Meier survival method was used to explore the difference in the P.aeruginosa free survival rates between CD14 genotype groups. As children in the study were not the same age, data was censored for individual children who were known to have not isolated P.aeruginosa at the time of their last BAL and this information was incorporated into the analysis. Breslow test (Breslow Generalized Wilcoxon Test) was employed to compare the difference in the survival curves of acquisition of P. aeruginosa in the three CD14 genotype groups. Multivariate Cox regression was used to estimate the relative risks after adjustment for potential confounding factors including age, sex, CFTR mutation and nutritional status. Plasma sCD14 levels were analysed by ANOVA and all the statistical analyses were performed using SPSS for Windows (Version 11).
###end p 10
###begin p 11
###xml 15 27 <span type="species:ncbi:9606">participants</span>
Parents of all participants gave informed consent and the Ethics Committee of King Edward Memorial and Princess Margaret Hospitals, Western Australia, approved the study.
###end p 11
###begin title 12
Results
###end title 12
###begin p 13
###xml 482 494 482 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P.aeruginosa</italic>
###xml 593 606 593 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P.aeruginosa </italic>
###xml 761 774 761 774 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P.aeruginosa </italic>
###xml 11 19 <span type="species:ncbi:9606">children</span>
###xml 482 494 <span type="species:ncbi:287">P.aeruginosa</span>
###xml 593 605 <span type="species:ncbi:287">P.aeruginosa</span>
###xml 633 641 <span type="species:ncbi:9606">children</span>
###xml 761 773 <span type="species:ncbi:287">P.aeruginosa</span>
Forty-five children (22 male), aged 0.6-6.6 years (mean 3.25 years) were studied, of whom 25/45 (55%) were DF508 homozygous and 20/45 DF508 heterozygous. CF was diagnosed at a mean age of 0.23 yrs (95%CI 0.06-0.4 yrs), with 73% diagnosed in the newborn period. There was no significant difference between CFTR mutation (p = 0.74), gender (p = 0.38), nutritional status (weight for height z scores) (p = 0.39) or socio-economic status (p = 0.29) in those who did and did not isolate P.aeruginosa. CD14 genotype frequencies at position -159 were: CC 12/45 (27%), CT 20/45 (44%), TT 13/45 (29%). P.aeruginosa was isolated from thirteen children (29%) and the mean age of acquisition was 2.26 years (95% CI 1.29-3.25). Subjects with CD14 -159CC appeared to isolate P.aeruginosa at a younger age (mean = 1.1 years, 95%CI = 0.2-1.9 years) than -159CT (mean = 2.8 years, 95%CI = 1.3-4.2 years) and TT subjects (mean = 3.3 years), although this difference was not statistically significant (p = 0.19).
###end p 13
###begin p 14
###xml 7 8 7 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 19 32 19 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P.aeruginosa </italic>
###xml 134 147 134 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P.aeruginosa </italic>
###xml 358 371 358 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P.aeruginosa </italic>
###xml 19 31 <span type="species:ncbi:287">P.aeruginosa</span>
###xml 107 115 <span type="species:ncbi:9606">children</span>
###xml 134 146 <span type="species:ncbi:287">P.aeruginosa</span>
###xml 189 197 <span type="species:ncbi:9606">children</span>
###xml 233 241 <span type="species:ncbi:9606">children</span>
###xml 267 275 <span type="species:ncbi:9606">children</span>
###xml 323 331 <span type="species:ncbi:9606">children</span>
###xml 358 370 <span type="species:ncbi:287">P.aeruginosa</span>
Figure 1 shows the P.aeruginosa free survival curves of the three CD14 genotype groups. The probability of children remaining free of P.aeruginosa with -159CC is consistently below that of children who are CT or TT and the curve for children with CT is below that of children with TT. For example, at 2 years of age, the % children remaining uninfected with P.aeruginosa is 55% vs. 82% vs. 100% for CC, CT and TT respectively.
###end p 14
###begin p 15
###xml 59 72 59 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P.aeruginosa </italic>
###xml 88 89 88 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 138 139 138 139 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 40 48 <span type="species:ncbi:9606">children</span>
###xml 59 71 <span type="species:ncbi:287">P.aeruginosa</span>
Kaplan-Meier estimates of proportion of children free from P.aeruginosa by CD14 C-159T. 1Breslow Test (Breslow Generalized Wilcoxon Test) 2"Censored" represents the censored observations that arise when the duration of a study is limited.
###end p 15
###begin p 16
###xml 258 270 258 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P.aeruginosa</italic>
###xml 661 673 661 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P.aeruginosa</italic>
###xml 848 861 848 861 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P.aeruginosa </italic>
###xml 22 30 <span type="species:ncbi:9606">children</span>
###xml 123 131 <span type="species:ncbi:9606">children</span>
###xml 258 270 <span type="species:ncbi:287">P.aeruginosa</span>
###xml 362 370 <span type="species:ncbi:9606">children</span>
###xml 661 673 <span type="species:ncbi:287">P.aeruginosa</span>
###xml 848 860 <span type="species:ncbi:287">P.aeruginosa</span>
Compared with -159TT, children with the CC genotype had a 10-fold (95%CI = 1.09-92.30, p = 0.042) higher relative risk and children with the CT genotype had an intermediate 5.5 fold (95%CI = 0.69-44.63, p = 0.108) higher relative risk of being infected with P.aeruginosa. After adjustment for CFTR mutation and nutritional status, the estimated relative risk in children with CC or CT increased further (RR = 13.32, 95%CI = 1.37-129.13, p = 0.025 and RR = 6.0, 95%CI = 0.71-51.03, p = 0.101 respectively). This suggested that independent of CFTR mutation and nutritional status, those with the C allele had a significantly increased risk of being infected with P.aeruginosa. In addition, there was a significant linear trend across the three genotype groups, between increasing numbers of C alleles and increasing likelihood of being infected with P.aeruginosa (p = 0.015).
###end p 16
###begin p 17
###xml 47 59 47 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P.aeruginosa</italic>
###xml 88 101 88 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P.aeruginosa </italic>
###xml 12 20 <span type="species:ncbi:9606">children</span>
###xml 47 59 <span type="species:ncbi:287">P.aeruginosa</span>
###xml 88 100 <span type="species:ncbi:287">P.aeruginosa</span>
Compared to children who subsequently isolated P.aeruginosa, those who remained free of P.aeruginosa had significantly higher plasma sCD14 levels: 1339.43 mug/ml (95%CI 1096.63-1635.98 mug/ml) vs. 492.75 mug/ml (95%CI 55.7-4359.01 mug/ml), p = 0.018. We found no significant association between plasma sCD14 levels and CD14 C-159T (p = 0.38).
###end p 17
###begin title 18
Discussion
###end title 18
###begin p 19
###xml 78 92 78 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. aeruginosa </italic>
###xml 197 209 197 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P.aeruginosa</italic>
###xml 78 91 <span type="species:ncbi:287">P. aeruginosa</span>
###xml 95 103 <span type="species:ncbi:9606">children</span>
###xml 197 209 <span type="species:ncbi:287">P.aeruginosa</span>
###xml 271 278 <span type="species:ncbi:9606">infants</span>
This study showed an association between CD14 -159CC and early acquisition of P. aeruginosa in children with CF. Many CF centres promote aggressive treatment regimes to eradicate first isolates of P.aeruginosa, and, thus, prospectively identifying a "high risk" group of infants with CF could have substantial clinical benefit.
###end p 19
###begin p 20
###xml 208 221 208 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P.aeruginosa </italic>
###xml 343 356 343 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P.aeruginosa </italic>
###xml 174 182 <span type="species:ncbi:9606">children</span>
###xml 208 220 <span type="species:ncbi:287">P.aeruginosa</span>
###xml 343 355 <span type="species:ncbi:287">P.aeruginosa</span>
CD14 receptor activation results in a strong Th1 cytokine response, directed through IL-12, in an attempt to eradicate pathogens. The finding of lower plasma sCD14 levels in children who subsequently isolate P.aeruginosa suggests that an inadequate pro-inflammatory response to LPS may place these individuals with CF at greater risk of early P.aeruginosa acquisition. The lack of association between CD14 C-159T and plasma sCD14 levels may merely reflect the small number of subjects in this population, but may also indicate that in CF there are factors more critical than CD14 C-159T genotype that determine plasma sCD14 levels.
###end p 20
###begin p 21
###xml 99 111 99 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P.aeruginosa</italic>
###xml 516 528 516 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P.aeruginosa</italic>
###xml 722 736 722 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. aeruginosa </italic>
###xml 9 17 <span type="species:ncbi:9606">children</span>
###xml 99 111 <span type="species:ncbi:287">P.aeruginosa</span>
###xml 271 279 <span type="species:ncbi:9606">patients</span>
###xml 516 528 <span type="species:ncbi:287">P.aeruginosa</span>
###xml 722 735 <span type="species:ncbi:287">P. aeruginosa</span>
###xml 745 753 <span type="species:ncbi:9606">children</span>
Although children with higher sCD14 levels may be relatively protected from earlier acquisition of P.aeruginosa, when they become colonised they may paradoxically have a worse outcome, as a result of an over-aggressive and ineffectual inflammatory response. These latter patients might potentially benefit from aggressive anti-inflammatory treatment. Thus, the timing of anti-inflammatory therapy would need to be carefully considered, as inflammation might be beneficial in early life by delaying colonisation with P.aeruginosa, but harmful once infection is established, due to the over-exuberant inflammatory response. Therapy that modulates the inflammatory response might promote the acquisition of pathogens such as P. aeruginosa in young children with different genetic susceptibilities.
###end p 21
###begin p 22
###xml 299 300 299 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 335 336 335 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 366 367 366 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 403 416 403 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P.aeruginosa </italic>
###xml 614 626 614 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P.aeruginosa</italic>
###xml 732 744 732 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P.aeruginosa</italic>
###xml 403 415 <span type="species:ncbi:287">P.aeruginosa</span>
###xml 419 427 <span type="species:ncbi:9606">children</span>
###xml 614 626 <span type="species:ncbi:287">P.aeruginosa</span>
###xml 732 744 <span type="species:ncbi:287">P.aeruginosa</span>
The results of this study are based on a limited number of subjects due to the stringent inclusion criteria and the prospective longitudinal design. In addition, the potential role of other single nucleotide polymorphisms in genes involved in innate immunity such as Toll-like receptor 4 Asp299Gly [6], Toll-like receptor 2 Arg753Gln [6] and mannose binding lectin [7], may influence the acquisition of P.aeruginosa in children with CF and more detailed investigation of these pathways in CF is indicated. This study identified the potential association between a common genetic variant and the early isolation of P.aeruginosa. The CD14 promoter polymorphism may have a central function in determining the age of first isolation of P.aeruginosa, with the CC genotype conferring a higher risk of early isolation and the TT genotype being relatively protective, emphasising the importance of understanding the delicate balance between inflammation and infection that exists in CF.
###end p 22
###begin title 23
Acknowledgements
###end title 23
###begin p 24
###xml 27 35 <span type="species:ncbi:9606">children</span>
We would like to thank the children and families who participated in this study and acknowledge the technical assistance of Elizabeth Balding and Samantha Gard. This study was supported by The National Health and Medical Research Council and the Australian Cystic Fibrosis Research Trust.
###end p 24
###begin article-title 25
Seeking modifier genes in cystic fibrosis
###end article-title 25
###begin article-title 26
###xml 0 23 0 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pseudomonas aeruginosa </italic>
###xml 0 22 <span type="species:ncbi:287">Pseudomonas aeruginosa</span>
###xml 80 88 <span type="species:ncbi:9606">children</span>
Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis
###end article-title 26
###begin article-title 27
A polymorphism in the 5' flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E
###end article-title 27
###begin article-title 28
CD14-dependent airway neutrophil response to inhaled LPS: role of atopy
###end article-title 28
###begin article-title 29
###xml 27 34 <span type="species:ncbi:9986">rabbits</span>
###xml 40 56 <span type="species:ncbi:562">Escherichia coli</span>
Effect of CD14 blockade in rabbits with Escherichia coli pneumonia and sepsis
###end article-title 29
###begin article-title 30
Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease
###end article-title 30
###begin article-title 31
Impact of mannose-binding lectin on susceptibility to infectious disease
###end article-title 31

